RMA Australian Government Coat of Arms

 

The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the Veterans' Entitlements Act 1986.

 

Dated 18 February 2025.

 

 

 

 

 

 

 

 

 

 

Professor Terence Campbell AM

Chairperson

by and on behalf of

The Repatriation Medical Authority

 

 

Contents

1 Name

2 Commencement

3 Authority

4 Repeal

5 Application

6 Definitions

7 Kind of injury, disease or death to which this Statement of Principles relates

8 Basis for determining the factors

9 Factors that must exist

10 Relationship to service

11 Factors referring to an injury or disease covered by another Statement of Principles

Schedule 1 - Dictionary

1 Definitions

 

 


This is the Statement of Principles concerning malignant neoplasm of the endometrium (Balance of Probabilities) (No. 32 of 2025).

              This instrument commences on 25 March 2025.

This instrument is made under subsection 196B(3) of the Veterans' Entitlements Act 1986.

The Statement of Principles concerning malignant neoplasm of the endometrium No. 12 of 2016 (Federal Register of Legislation No. F2016L00244) made under subsection 196B(3) and (8) of the VEA is repealed.

This instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies.

The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.

Meaning of malignant neoplasm of the endometrium

  1.           For the purposes of this Statement of Principles, malignant neoplasm of the endometrium:
    1.           means a primary malignant neoplasm arising from the cells of the mucous membrane that line the uterine cavity; and
    2.           includes;
      1.             carcinoma in situ and
      2.          carcinosarcoma (also known as malignant mesodermal mixed tumour); and
    3.           excludes;
      1.             malignant neoplasm of the cervix;
      2.          carcinoid tumour;
      3.        soft tissue sarcoma of the uterus;
      4.         non-Hodgkin's lymphoma; and
      5.           Hodgkin's lymphoma.
  2.           While malignant neoplasm of the endometrium attracts ICD10AM code C54.1, in applying this Statement of Principles the meaning of malignant neoplasm of the endometrium is that given in subsection (2).
  3.           For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.

Death from malignant neoplasm of the endometrium

  1.           For the purposes of this Statement of Principles, malignant neoplasm of the endometrium, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's malignant neoplasm of the endometrium.

Note: terminal event is defined in the Schedule 1 – Dictionary.

On the sound medicalscientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that malignant neoplasm of the endometrium and death from malignant neoplasm of the endometrium can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.

Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.

At least one of the following factors must exist before it can be said that, on the balance of probabilities, malignant neoplasm of the endometrium or death from malignant neoplasm of the endometrium is connected with the circumstances of a person's relevant service:

  1.           for females aged over 35 years only, having never been pregnant for more than 8 weeks, at the time of clinical onset;
  2.           using oestrogen-only hormone replacement therapy for at least 6 months before clinical onset, and where the use of oestrogen-only hormone replacement therapy has ceased, clinical onset has occurred within 20 years of cessation;

Note: oestrogen-only hormone replacement therapy is defined in the Schedule 1 - Dictionary.

  1.           having cyclical combined hormone replacement therapy where oestrogen is combined with cyclical administration of progesterone for less than 15 days during each treatment cycle, for a continuous period of at least 5 years before clinical onset. Where the use of cyclical combined hormone replacement therapy has ceased, clinical onset has occurred within 5 years of cessation;
  2.           for post-menopausal females only, undergoing treatment with tamoxifen for at least 3 months before clinical onset, and where treatment has ceased, clinical onset has occurred within 20 years of cessation.
  3.           being overweight or obese for a period of at least 10 years within the 20 years before clinical onset;

Note: being overweight or obese is defined in the Schedule 1 - Dictionary.

  1.           having diabetes mellitus for at least 10 years before clinical onset;
  2.           an inability to undertake any physical activity greater than 3 METs for at least 10 years within the 30 years before clinical onset;

Note: MET is defined in the Schedule 1 - Dictionary.

  1.           Having undergone treatment with Tibolone for at least 1 year before clinical onset, and where treatment has ceased, clinical onset has occurred within 10 years of cessation.
  2.           inability to obtain appropriate clinical management for malignant neoplasm of the endometrium before clinical worsening.

In this Statement of Principles:

  1.           if a factor referred to in section 9 applies in relation to a person; and
  2.           that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;

then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.

 

 

Schedule 1 - Dictionary  

Note:               See Section 6

In this instrument:

                               being overweight or obese means having a Body Mass Index (BMI) of 25 or

                               greater.

Note; BMI is defined in the Schedule 1 – Dictionary.

                               BMI means W/H2

                               where:

                               W is the person's weight in kilograms; and

                               H is the person's height in metres.

                             malignant neoplasm of the endometrium—see subsection 7(2).

                             MET means a unit of measurement of the level of physical exertion.  1 MET = 3.5 ml of oxygen/kg of body weight per minute, 1.0 kcal/kg of body weight per hour or resting metabolic rate.

                             MRCA means the Military Rehabilitation and Compensation Act 2004.

                             oestrogen-only hormone replacement therapy means the continuous, cyclical or intermittent administration of unopposed oestrogen, including diethylstilbestrol, to combat surgically induced or naturally occurring menopause.

                             relevant service means:

(a)          eligible war service (other than operational service) under the VEA;

(b)          defence service (other than hazardous service and British nuclear test defence service) under the VEA; or

(c)          peacetime service under the MRCA.

Note: MRCA and VEA are also defined in the Schedule 1 - Dictionary.

                             terminal event means the proximate or ultimate cause of death and includes the following:

(a)           pneumonia;

(b)           respiratory failure;

(c)           cardiac arrest;

(d)           circulatory failure; or

(e)           cessation of brain function.

                             VEA means the Veterans' Entitlements Act 1986.